Eluminex Biosciences’ Acquisition of Zuretinol Acetate Assets from Retinagenix

Goodwin Procter advised Eluminex Biosciences on the deal.

Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights for a novel oral therapy, zuretinol acetate (zuretinol), from Retinagenix Holdings, LLC (Retinagenix). Zuretinol is an investigational treatment that is currently being developed to treat rare forms of childhood blindness in patients with Leber congenital amaurosis or retinitis pigmentosa caused by mutations of the RPE65 or LRAT gene.

Eluminex is a privately-held clinical-stage biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. The company is headquartered in Suzhou, China with a US-subsidiary office in the San Francisco Bay Area.

Retinagenix is a privately-held biotechnology company devoted to addressing the large and expanding unmet medical needs in genetically determined orphan diseases of the eye.

Under the terms of the asset purchase agreement, Eluminex will make an upfront payment and earnout payments to Retinagenix for the purchase of the assets. The earnout payments to Retinagenix shall include (a) clinical, regulatory, and commercial milestone payments and (b) payments based upon worldwide net sales of products and the sale or use of priority review vouchers.

The Goodwin team was led by Can Cui (Picture) and Maggie Wong, and included Marina Ahmad (Corporate), Dan Karelitz and Leon Peschel (Tax), Jacob Osborn and Amy Josselyn (Global Trade), and Paul Jin (Antitrust).


Involved fees earner: Marina Ahmad – Goodwin Procter; Can Cui – Goodwin Procter; Paul Jin – Goodwin Procter; Amy Josselyn – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Jacob Osborn – Goodwin Procter; Leon Peschel – Goodwin Procter; Maggie Wong – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Eluminex Biosciences;

Martina Bellini

Author: Martina Bellini